Document is current
Any future updates will be listed below
-
Authors
,
Naito, Yoichi
,
,
Aburatani, Hiroyuki
Amano, Toraji
Baba, Eishi
Furukawa, Toru
Hayashida, Tetsu
Hiyama, Eiso
Ikeda, Sadakatsu
Kanai, Masashi
Kato, Motohiro
Kinoshita, Ichiro
Kiyota, Naomi
Kohno, Takashi
Kohsaka, Shinji
Komine, Keigo
Matsumura, Itaru
Miura, Yuji
Nakamura, Yoshiaki
Natsume, Atsushi
Nishio, Kazuto
Oda, Katsutoshi
Oda, Naoyuki
Okita, Natsuko
Oseto, Kumiko
Sunami, Kuniko
Takahashi, Hideaki
Takeda, Masayuki
Tashiro, Shimon
Toyooka, Shinichi
Ueno, Hideki
Yachida, Shinichi
Yoshino, Takayuki
Tsuchihara, Katsuya https://orcid.org/0000-0001-7507-2349
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (19EA1001)
- License Information
-
More Information
Article History
Received: 22 October 2020
Accepted: 30 October 2020
First Online: 29 November 2020
Compliance with ethical standards
:
: Yoichi Naito received honoraria from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Pfizer Japan Inc., and research funding from AstraZeneca K.K., Eli Lilly Japan K.K., Pfizer Japan Inc., Roche (Ignyta Inc.). Hiroyuki Aburatani received research funding from Chugai Pharmaceutical Co., Ltd., BrightPath Biotherapeutics Co., Ltd., Hitachi Ltd., Fujitsu Ltd., Kyowa Kirin Co., Ltd., and Kowa Co., Ltd.. Eishi Baba received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., research funding from Mediscience Planning Inc. and MSD K.K., and scholarship donations from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Merck Biopharma Co., Ltd, Takeda Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. Toru Furukawa received research funding from Tokyo Central Pathology Laboratory Co., Ltd. and Annai Yakkyoku Co., Ltd. Tetsu Hayashida received honoraria from Eisai Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K., research funding from Novartis Pharma K.K., Denka Co., Ltd., and Shionogi Co., Ltd., and scholarship donations from Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Eisai Co., Ltd. Sadakatsu Ikeda received research funding from ACT Genomics Co., Ltd. Masashi Kanai received stock ownership from Therabiopharma Inc. and honoraria from Chugai Pharmaceutical Co., Ltd. Motohiro Kato received research funding from Daiichi Sankyo Co., Ltd. Naomi Kiyota received honoraria from Ono Pharmaceutical Co., Ltd., Bristol-Meyers Squibb K.K., Eisai Co., Ltd., and Bayer Yakuhin Ltd., and research funding from Ono Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Takashi Kohno received research funding from Sysmex Corp. Shinji Kohsaka received research funding from AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd. Itaru Matsumura received honoraria from Novartis Pharma K.K., Bristol-Meyers Squibb K.K., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Amgen Astellas BioPharma Inc., and research funding from Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi Co., Ltd., AbbVie G.K., Asahi Kasei Corp., Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Yuji Miura received honoraria from Ono Pharmaceutical Co., Ltd., Bristol-Meyers Squibb K.K., MSD K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., and Takeda Pharmaceutical Co., Ltd., and scholarship donations from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Shionogi Co., Ltd., and Eisai Co., Ltd.. Atsushi Natsume has an employment/leadership position/advisory role of NGK Spark Plug Co., Ltd., and received honoraria from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd, Nippon Kayaku Co., Ltd., and Eisai Co., Ltd. Kazuto Nishio received honoraria from Sumitomo Bakelite Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Eisai Co., Ltd., and Chugai Pharmaceutical Co., Ltd., fees for promotional materials from Eisai Co., Ltd., and research funding from Korea Otsuka Pharmaceutical Co., Ltd., Life Technologies Japan Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ignyta Inc., and Eli Lilly Japan K.K. Katsutoshi Oda received honoraria from AstraZeneca K.K., and Chugai Pharmaceutical Co Ltd., and research funding from AstraZeneca K.K., and Daiichi Sankyo Co. Ltd. Kumiko Oseto has an employment/leadership position/advisory role of Konica Minolta Precision Medicine Japan, Inc. Shinichi Toyooka received honoraria from Astellas Pharma Inc., Taiho Pharmaceutical Co. Ltd., and Eisai Co., Ltd., and research funding from Mitsui E&S Holding Co. Ltd., Eufofins Clinical Genetics Co., Ltd., Daiichi Sankyo Co. Ltd., Yamada Bee Company, Inc., and SBI Life Insurance Co. Ltd. Takayuki Yoshino received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., and Merck Biopharma Co., Ltd, and research funding from MSD K.K., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Sanofi K.K., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Parexel International Inc. Other authors have no conflict of interest.
